Company with Rare Genetic Disorder Interests

Areas of Interest in Research and Collaboration

ONO Pharmaceutical Co, LTD is a global company with a wide range of therapeutic area expertise and products. Specific focus areas include oncology, diabetes, immunology and neurology. Through ONO’s Pharma Foundation, Discovery Research Alliance and Business Development Department, they currently support more than 300 research collaborations around the world including joint research, 1-on-1 and young principal investigator early collaborations.

In alliance with Innovation Partnerships and Michigan Medicine’s rare disease interest group (MIRARE), ONO is expanding its research and development efforts to identify potential collaborative research efforts focusing on rare genetic disorders with U-M faculty.

Genetic Disorders and Rare Diseases Research & Development Priorities

Rare Disease Priorities
- **Prevalence:** Between 1/10,000 to 1/100,000 population frequency
- **Mechanism/Cause:** Monogenic disorder/mechanism to allow for therapeutic intervention
- **Treatments:** Unmet need with no satisfactory treatment
- **Competitiveness:** Innovative research with first-in-class or best-in-class treatment potential

Out-of-Scope
- Treatment devices
- Diagnostics/screening equipment
- Drug repurposing, unless Intellectual Property can be firmly established
- Drug targets with approved treatments or treatments being developed by other biotech/pharmaceutical companies
- Rare cancers

Stage of Development
- Early-stage discovery with identified target
- Novel genetic therapeutic approaches with identified target
- Novel technology/platform that can be applied to multiple targets

If you have an idea for a possible collaborative project or want to learn more, please contact **Michael R Brandt, PhD** at mrbrandt@umich.edu. We can review your proposal and connect you with the team at Ono to discuss further.